Proteomics Analysis of Amniotic Fluid

Article

SMFM 27th Annual Meeting 2007

view the interview video: Proteomics of the Amniotic Fluid to Predict Preterm Birth

Abstract

Objective: Identification of relevant disease biomarkers that may impact prediction of preterm birth (PTB) and fetal outcome is critical. Recent advancement in proteomics has provided a valuable perspective related to several complex functional and molecular mechanisms (inflammation, bleeding) leading to PTB. Still, the etiology of most PTB remains elusive. A comprehensive analysis of the amniotic fluid (AF) proteome was conducted to identify disease biomarker patterns related to PTB in the absence of infection/inflammation or bleeding.

Study Design: A proteomic fingerprint was generated from fresh AF using SELDI-TOF mass spectrometry in a total of 268 consecutive samples retrieved from women who presented with signs or symptoms of preterm labor or PPROM. Intra-amniotic inflammation and bleeding were excluded based on previously validated proteomic profiles and biomarker identification. Hierarchical clustering algorithms based on novel descriptors quantifying similarity/dissimilarity among tracings allowed identification of mass areas of interest.

Results: The prevalence of PTB <34 wks was 77%. A novel discriminatory profile was identified in the 10-14 kDa area of interest and consisted of 5 proteomic peaks (Q1-5; Figure). The abnormal profile was associated with PTB in the absence of intra-amniotic infection, inflammation or bleeding. Women displaying the novel profile were at 27.1 [16.3-36.1] wks GA at amniocentesis and most often presented with intact membranes. The novel profile appeared alone and all other tests of AF were normal in 85% (17/20) of cases.

Conclusion: Proteomic profiling of the AF coupled with novel mathematical algorithms can be used to identify patients at risk for PTB in the absence of intra-amniotic inflammation or bleeding.


References:

0002-9378/$ - see front matter

doi:10.1016/j.ajog.2006.10.018

American Journal of Obstetrics and Gynecology

Volume 195, Issue 6, Supplement S (December 2006)

Recent Videos
Laurence Shields, MD, is System Physician Vice President at the Women and Infants Clinical Institute with CommonSpirit Health in Santa Maria, California.
Mirvie's RNA platform revolutionizes detection of fetal growth restriction | Image Credit: wexnermedical.osu.edu
How maternal fetal medicine specialists improve outcomes for high-risk pregnancies | Image Credit: profiles.mountsinai.org
Screening-to-diagnosis interval vital for gestational diabetes outcomes | Image Credit: ultracon2024.eventscribe.net
Henri M. Rosenberg, MD
Study explores the limits of neighborhood data in predicting preterm birth | Image Credit: linkedin.com
Barbed suture reduces blood loss in hysterectomy | Image Credit: linkedin.com
Integrase inhibitors not linked to neonatal weight | Image Credit: linkedin.com
How AI is revolutionizing prenatal detection of congenital heart defects | Image Credit: mfmnyc.com/team.
Sheryl Kingsberg, PhD: Psychedelic RE104 for postpartum depression
Related Content
© 2025 MJH Life Sciences

All rights reserved.